Discover trends, market shifts, and competitive outlooks for the liquid biopsy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Liquid Biopsy Market Expected to Grow Between 2025 And 2029?

The size of the liquid biopsy market has experienced considerable expansion in the past few years. It is set to proliferate from $1.25 billion in 2024 to $1.46 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.4%. This growth observed in the historical period is the result of accomplishments in cancer research, non-intrusive procedures, personalized care, regulatory approvals, and potential for early detection of cancer.

The market for liquid biopsies is predicted to grow substantially in the upcoming years, reaching a value of $2.76 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 17.2%. The anticipated growth during the forecast period is largely due to the expanding applications of liquid biopsy for cancer monitoring, the development of new technologies, the emergence of companion diagnostics, and biomarker discovery. Noteworthy trends expected in the forecast period encompass cancer detection and surveillance, therapeutic monitoring, minimal residual disease (mrd) monitoring, and the use of liquid biopsies in fields beyond oncology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

What Are the Core Market Drivers Propelling Growth in the Liquid Biopsy Industry?

The expansion of the liquid biopsy market is propelled by government funding aimed at enhancing cancer detection techniques. Such funding serves as a significant aid to researchers in developing drugs, diagnosing, and treating diseases, specifically Cancer. For instance, in 2022, the National Institute of Health (NIH), a medical research agency in the US, received a grant of $46.6 billion. Moreover, the National Cancer Institute (NCI), which specializes in cancer research in America, was allocated $6.9 billion to boost cancer research. Thus, the liquid biopsy market’s growth is greatly benefitted from these government funds.

How Is the Liquid Biopsy Market Segmented?

The liquid biopsy market covered in this report is segmented –

1) By Product: Assays Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring Orthopedics

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assays Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays, Protein-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments, Mass Spectrometry Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services, Custom Assay Development Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2815&type=smp

Which Regions Are Driving the Next Phase of the Liquid Biopsy Market Growth?

North America was the largest region in the liquid biopsy market in 2023. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Liquid Biopsy Market?

Companies are swiftly embracing new market trends, primarily concentrating on innovative product rollouts, in order to fulfill the growing demand for liquid biopsy products and services. This not only boosts their revenue but also sets them apart from competitors. For example, in June 2023, the US-based healthcare firm, Laboratory Corporation of America Holdings, introduced a liquid biopsy test named Labcorp Plasma Focus. This test identifies cancer-related biomarkers in patients affected by advanced or metastatic solid tumors. The test analyzes the cell-free DNA (cfDNA) circulating in the patient’s blood to create a tumor genomic profile. This assists oncologists in improving their patient’s healthcare management by designing specifically targeted, personalized therapy strategies. As a result, companies are making significant investments in the creation of advanced products in the liquid biopsy market.

View the full report here:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

How Is the Liquid Biopsy Market Defined and What Are Its Core Parameters?

A liquid biopsy is a quick and painless substitute for surgical biopsies that allows medical professionals to learn a lot about a tumor from a small blood sample. A liquid biopsy is a diagnostic test performed on blood to detect the presence of any cancerous cells in the blood. It is used to detect cancer at an early stage.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2815

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model